BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31301955)

  • 1. Soluble urokinase plasminogen activator receptor in type 1 diabetic children, relation to vascular complications.
    Sherif EM; El Maksood AAA; Youssef OI; Salah El-Din NY; Khater OKM
    J Diabetes Complications; 2019 Sep; 33(9):628-633. PubMed ID: 31301955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes.
    Theilade S; Lyngbaek S; Hansen TW; Eugen-Olsen J; Fenger M; Rossing P; Jeppesen JL
    J Intern Med; 2015 Mar; 277(3):362-371. PubMed ID: 24830873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble urokinase plasminogen activator receptor (suPAR) in children with obesity or type 1 diabetes as a marker of endothelial dysfunction: a cross-sectional study.
    Kostopoulou E; Kalavrizioti D; Davoulou P; Sinopidis X; Papachristou E; Goumenos DS; Dimitriou G; Spiliotis BE; Papasotiriou M
    Eur J Pediatr; 2024 May; 183(5):2383-2389. PubMed ID: 38448612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
    Rotbain Curovic V; Theilade S; Winther SA; Tofte N; Eugen-Olsen J; Persson F; Hansen TW; Jeppesen J; Rossing P
    Diabetes Care; 2019 Jun; 42(6):1112-1119. PubMed ID: 30885954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for the development of micro-vascular complications of type 2 diabetes in a single-centre cohort of patients.
    Teliti M; Cogni G; Sacchi L; Dagliati A; Marini S; Tibollo V; De Cata P; Bellazzi R; Chiovato L
    Diab Vasc Dis Res; 2018 Sep; 15(5):424-432. PubMed ID: 29911415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urokinase plasminogen activator receptor and its soluble form in common biopsy-proven kidney diseases and in staging of diabetic nephropathy.
    Wu CZ; Chang LC; Lin YF; Hung YJ; Pei D; Chu NF; Chen JS
    Clin Biochem; 2015 Dec; 48(18):1324-9. PubMed ID: 26162494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland.
    Ebeling P; Koivisto VA
    Acta Diabetol; 1997 Mar; 34(1):33-8. PubMed ID: 9134055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasminogen activator inhibitor-1 (PAI-1) in children and adolescents with type 1 diabetes mellitus: relation to diabetic micro-vascular complications and carotid intima media thickness.
    Adly AA; Elbarbary NS; Ismail EA; Hassan SR
    J Diabetes Complications; 2014; 28(3):340-7. PubMed ID: 24581943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study.
    Crook MA; Pickup JC; Lumb PJ; Giorgino F; Webb DJ; Fuller JH;
    Diabetes Care; 2001 Feb; 24(2):316-22. PubMed ID: 11213885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging measures of decreased aortic strain and distensibility are proportionate to insulin resistance in adolescents with type 1 diabetes mellitus.
    McCulloch MA; Mauras N; Canas JA; Hossain J; Sikes KM; Damaso LC; Redheuil A; Ross JL; Gidding SS
    Pediatr Diabetes; 2015 Mar; 16(2):90-7. PubMed ID: 25524487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycaemic control and microvascular complications in a large cohort of Italian Type 1 diabetic out-patients.
    Lepore G; Bruttomesso D; Nosari I; Tiengo A; Trevisan R
    Diabetes Nutr Metab; 2002 Aug; 15(4):232-9. PubMed ID: 12416660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early diabetic complications in a population of young patients with type 1 diabetes mellitus despite intensive treatment.
    Nordwall M; Hyllienmark L; Ludvigsson J
    J Pediatr Endocrinol Metab; 2006 Jan; 19(1):45-54. PubMed ID: 16509528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Urokinase-type Plasminogen Activator Receptor and its Soluble Form in Type 2 Diabetic Kidney Disease.
    Zhou Y; Ren J; Li P; Ma R; Zhou M; Zhang N; Kong X; Hu Z; Xiao X
    Arch Med Res; 2019 Jul; 50(5):249-256. PubMed ID: 31593848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kallistatin as a marker of microvascular complications in children and adolescents with type 1 diabetes mellitus: Relation to carotid intima media thickness.
    El-Asrar MA; Andrawes NG; Ismail EA; Salem SM
    Vasc Med; 2015 Dec; 20(6):509-17. PubMed ID: 26091968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: The Rio de Janeiro Type 2 Diabetes Cohort Study.
    Cardoso CRL; Leite NC; Moram CBM; Salles GF
    Cardiovasc Diabetol; 2018 Feb; 17(1):33. PubMed ID: 29477146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of Microvascular Complications and Effect of Concurrent Risk Factors in Type 1 Diabetes: A Multistate Model From an Observational Clinical Cohort Study.
    Bjerg L; Hulman A; Carstensen B; Charles M; Jørgensen ME; Witte DR
    Diabetes Care; 2018 Nov; 41(11):2297-2305. PubMed ID: 30131399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM.
    Hofmann MA; Kohl B; Zumbach MS; Borcea V; Bierhaus A; Henkels M; Amiral J; Schmidt AM; Fiehn W; Ziegler R; Wahl P; Nawroth PP
    Diabetes Care; 1998 May; 21(5):841-8. PubMed ID: 9589252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum soluble urokinase plasminogen activator receptor as a potential biomarker of renal impairment severity in diabetic nephropathy.
    Lupușoru G; Ailincăi I; Sorohan BM; Andronesi A; Achim C; Micu G; Caragheorgheopol A; Manda D; Lupușoru M; Ismail G
    Diabetes Res Clin Pract; 2021 Dec; 182():109116. PubMed ID: 34728182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The association between retinopathy, nephropathy, cardiovascular disease and long-term metabolic control in type 1 diabetes mellitus: a 5 year follow-up study of 442 adult patients in routine care.
    Agardh CD; Agardh E; Torffvit O
    Diabetes Res Clin Pract; 1997 Mar; 35(2-3):113-21. PubMed ID: 9179466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes.
    Berg TJ; Snorgaard O; Faber J; Torjesen PA; Hildebrandt P; Mehlsen J; Hanssen KF
    Diabetes Care; 1999 Jul; 22(7):1186-90. PubMed ID: 10388987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.